SY-001 by CellOrigin Technology (Hangzhou) for Solid Tumor: Likelihood of Approval

SY-001 is under clinical development by CellOrigin Technology (Hangzhou) and currently in Phase I for Solid Tumor.

Infinity Pharmaceuticals lays off 78% of staff, shrinks board after MEI merger fail

Infinity Pharmaceuticals is scrambling to reduce its “burn rate” after the proposed merger with MEI Pharma fell through, turning to layoffs and a downsized board

July 27, 2023

Biden and Trump are fighting to claim credit for $35 insulin. It was actually a pharma giant’s idea

WASHINGTON — Both President Biden and former President Trump love to claim credit for getting more Americans $35 insulin. But the credit should actually go

June 13, 2024

Boston Scientific to buy Axonics for $3.7B to gain incontinence treatment

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Boston Scientific said Monday it

January 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.